Martin Wermke

8.1k total citations · 1 hit paper
152 papers, 3.7k citations indexed

About

Martin Wermke is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Martin Wermke has authored 152 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Oncology, 35 papers in Hematology and 34 papers in Immunology. Recurrent topics in Martin Wermke's work include CAR-T cell therapy research (51 papers), Cancer Immunotherapy and Biomarkers (32 papers) and Acute Myeloid Leukemia Research (24 papers). Martin Wermke is often cited by papers focused on CAR-T cell therapy research (51 papers), Cancer Immunotherapy and Biomarkers (32 papers) and Acute Myeloid Leukemia Research (24 papers). Martin Wermke collaborates with scholars based in Germany, United States and France. Martin Wermke's co-authors include Gerhard Ehninger, Martin Bornhäuser, Christian Thiede, Uwe Platzbecker, Brigitte Mohr, Markus Schaich, Thomas Illmer, Christine Steudel, Ulrike Schäkel and Markus Ritter and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Martin Wermke

137 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

2002 1.3k citations Uwe Platzbecker, Martin Wermke et al. Blood profile →

Peers

Countries citing papers authored by Martin Wermke

Since Specialization

Citations

This map shows the geographic impact of Martin Wermke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Wermke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Wermke more than expected).

Fields of papers citing papers by Martin Wermke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Wermke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Wermke. The network helps show where Martin Wermke may publish in the future.

Co-authorship network of co-authors of Martin Wermke

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Wermke. A scholar is included among the top collaborators of Martin Wermke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Wermke. Martin Wermke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deidentifying Medical Documents with Local, Privacy-Preserving Large Language Models: The LLM-Anonymizer 2025 ·NEJM AI ·Isabella C. Wiest, (unknown), F M Wolf, Dyke Ferber, Marko van Treeck, (unknown), Matthias P. Ebert, C. Benedikt Westphalen, Martin Wermke, Jakob Nikolas Kather	10
2	Histologic Transformation in Cancer: The Path for Clinical Translation 2025 ·Cancer Discovery ·Ioannis Vathiotis, Avisek Banerjee, Utsav Sen, Felix Carl Saalfeld, Debdatta Halder, Andriani Charpidou, K. Syrigos, Hidehito Horinouchi, Ashutosh Tewari, Mark A. Dawson, Martin Wermke, Triparna Sen	0
3	Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas 2025 ·Journal of Clinical Oncology ·Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Enriqueta Felip, Miguel F. Sanmamed, Olatunji B. Alese, Cyrus Sayehli, Edurne Arriola, Juergen Wolf, Liza C. Villaruz, (unknown), Matus Studeny, (unknown), Xiaoyan Fang, Daniel Morgensztern	4
4	First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms 2025 ·Cancers* ·Simone Thomas, Martin Wermke, Vladan Vučinić, Eva Wagner-Drouet, (unknown), Robert Zeiser, Gesine Bug, Michael Schmitt, Wolfgang Herr, Petra U. Prinz, Maja Bürdek, Silke Raffegerst, Agostino Tafuri, (unknown), (unknown), (unknown), Kai Pinkernell, Dolores J. Schendel	0
5	2757O Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study 2025 ·Annals of Oncology ·Martin Wermke, Sally C. M. Lau, (unknown), (unknown), Kelly G. Paulson, (unknown), (unknown), (unknown), (unknown), Michael Boyer, (unknown), Andrew Parkes, (unknown), Anahita Hamidi, (unknown), (unknown)	0
6	1600O Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial 2025 ·Annals of Oncology ·Sapna P. Patel, Apostolia M. Tsimberidou, Jason J. Luke, Winfried Alsdorf, Antonia Busse, (unknown), (unknown), Norbert Hilf, M. Alper Kursunel, Andrea Mayer-Mokler, Dmitry Pankov, Cedrik M. Britten, Martin Wermke, Leonel F. Hernandez‐Aya	0
7	Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study 2024 ·British Journal of Haematology ·Christoph Röllig, Christoph Schliemann, Leo Ruhnke, Lars Fransecky, (unknown), Maher Hanoun, Richard Noppeney, Kerstin Schäfer‐Eckart, Knut Wendelin, Jan‐Henrik Mikesch, Jan Moritz Middeke, Manja Reimann, (unknown), Sven Zukunft, Martin Wermke, Hubert Serve, Uwe Platzbecker, Carsten Müller‐Tidow, Claudia D. Baldus, Martin Bornhäuser	3
8	1300P Treatment sequences in BRAF-V600-mutant non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy 2024 ·Annals of Oncology ·(unknown), (unknown), (unknown), Felix Carl Saalfeld, Michael Rost, Charles Elias Assmann, Franziska Herster, (unknown), (unknown), Cornelia Kropf-Sanchen, (unknown), (unknown), Albrecht Stenzinger, (unknown), (unknown), Martin Wermke, Nikolaj Frost, H-G. Kopp, Petros Christopoulos, (unknown)	0
9	Zielgerichtete Systemtherapie beim operablen Lungenkarzinom 2024 ·Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie ·(unknown), Felix Carl Saalfeld, Daniela E. Aust, (unknown), (unknown), (unknown), D Baum, Martin Wermke, Till Ploenes	1
10	119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study 2023 ·Immuno-Oncology Technology ·Theresa Medina, Jason Chesney, Eric D. Whitman, Harriet M. Kluger, Sajeve Thomas, Amod Sarnaik, John M. Kirkwood, James Larkin, Jeffrey S. Weber, Omid Hamid, Martin Wermke, Friedrich Graf Finckenstein, Jeffrey Chou, Brian Gastman, (unknown), Xiao Wu, Wen Shi, (unknown)	7
11	75MO Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts 2023 ·Annals of Oncology ·Yasutoshi Kuboki, Valentina Gambardella, (unknown), Olatunji B. Alese, Daniel Morgensztern, Cyrus Sayehli, Miguel F. Sanmamed, Edurne Arriola, Jennifer Moriatis Wolf, Taofeek K. Owonikoko, Matus Studeny, (unknown), Erwei Song, Martin Wermke	0
12	Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma 2023 ·Blood ·Fredrik Schjesvold, Andrew Spencer, Yaël C. Cohen, Enrique M. Ocio, (unknown), Anna Maria Cafro, Natalie S. Callander, Jonathan L. Kaufman, Meera Mohan, Martin Wermke, (unknown), Rebecca Kan, (unknown), Gina M. Trabucco, (unknown), Romain Séchaud, Cornelia Quadt, Raghav Chawla, Marc S. Raab	3
13	1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy 2023 ·Annals of Oncology ·(unknown), Jörg Möller, Sebastian Michels, Christian Grohé, Marcel Wiesweg, Christoph D. Schubart, (unknown), Frank Griesinger, Diego Kauffmann‐Guerrero, (unknown), Tobias R. Overbeck, (unknown), Gernot Rohde, Claas Wesseler, Ioannis Vathiotis, Rajwanth Veluswamy, (unknown), Sacha I. Rothschild, Petros Christopoulos, Martin Wermke	1
14	1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC 2023 ·Annals of Oncology ·Lucia Nogová, Florian Malchers, Axel M. Hillmer, (unknown), (unknown), Sabine Merkelbach‐Bruse, Andreas H. Scheel, Janna Siemanowski, Matthias Scheffler, John Frank, (unknown), (unknown), Martin Wermke, Christian Grohé, Anna Kron, Niels Reinmuth, Frank Griesinger, Roman K. Thomas, Reinhard Büttner, Jennifer Moriatis Wolf	2
15	2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3 2023 ·Annals of Oncology ·Julien Mazières, M. Duruisseaux, (unknown), Chigusa Morizane, Rachel Galot, Sylvie Rottey, Jan Stratmann, Yuchao Ma, (unknown), (unknown), Martin Wermke	1
16	OA01.05 Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC 2023 ·Journal of Thoracic Oncology ·Martin Wermke, Yasutoshi Kuboki, Enriqueta Felip, Olatunji B. Alese, Daniel Morgensztern, Cyrus Sayehli, Edurne Arriola, Miguel F. Sanmamed, (unknown), Erwei Song, Matus Studeny, Valentina Gambardella	3
17	Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse 2022 ·SHILAP Revista de lepidopterología ·Katja Sockel, Friedrich Stölzel, (unknown), (unknown), Christoph Röllig, Martin Wermke, Malte von Bonin, Raphael Teipel, (unknown), (unknown), Frank Kroschinsky, Mathias Hänel, Anke Morgner, (unknown), Gerhard Ehninger, Uwe Platzbecker, Martin Bornhäuser, Johannes Schetelig, Jan Moritz Middeke	3
18	Peptidyl prolyl cis/trans isomerase activity on the cell surface correlates with extracellular matrix development 2019 ·Communications Biology ·Weilin Lin, Malte von Bonin, Annett Boden, Robert Wieduwild, Priyanka Murawala, Martin Wermke, Helena Andrade, Martin Bornhäuser, Yixin Zhang	25
19	Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma 2019 ·Blood ·Max S. Topp, Tom van Meerten, Roch Houot, Monique C. Minnema, Nöel Milpied, Pieternella J. Lugtenburg, Catherine Thiéblemont, Martin Wermke, Kevin Song, Irit Avivi, John Kuruvilla, Ulrich Dührsen, (unknown), Lianqing Zheng, Vicki Plaks, A. Kerber, Marie José Kersten	42
20	MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation 2012 ·Clinical Cancer Research ·Martin Wermke, Anne Schmidt, Jan Moritz Middeke, Katja Sockel, Malte von Bonin, (unknown), Sabine Mair, Verena Plodeck, Michael Laniado, Günter Weiß, Johannes Schetelig, Gerhard Ehninger, Igor Theurl, Martin Bornhäuser, Uwe Platzbecker	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact